Abiomed's Newest Impella Pump Earns CE Mark

Reed Miller


April 12, 2012

April 12, 2012 (Danvers, Massachusetts) — Abiomed's Impella cVAD percutaneous temporary circulatory support device will be commercially available in Europe sometime this summer, the company announced following confirmation of a CE Mark for the device [1].

The pump can provide peak flow of approximately 4 L of blood per minute. The older version of the Impella pump, the Impella 2.5, delivers up to 2.5 L of blood per minute. Both devices are implanted percutaneously and use the same console platform, 9-F catheter, and introducer.

The Impella cVAD is indicated for up to five days of temporary circulatory support in patients with reduced left ventricular function, including postcardiotomy patients or patients who have recently suffered cardiogenic shock or an MI. It can also be used for cardiovascular support during beating-heart surgery or high-risk PCIs.